Related Experiment Video
Updated: Apr 9, 2026
Generation of Human Cardiomyocytes: A Differentiation Protocol from Feeder-free Human Induced Pluripotent Stem Cells
Published on: June 28, 2013
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model for Heart Development and Congenital Heart
Michelle J Doyle1, Jamie L Lohr, Christopher S Chapman
1Lillehei Heart Institute, University of Minnesota, 2231 6th St SE, MMC 208, Minneapolis, MN, 55455, USA.
Insights
Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes offer a novel approach to study congenital heart disease (CHD). These models advance understanding of CHD development, pathophysiology, and personalized therapeutic targets.
Area of Science:
- Cardiology
- Stem Cell Biology
- Developmental Biology
Background:
- Congenital heart disease (CHD) affects a growing population of survivors with chronic conditions.
- The genetic basis and etiology of most CHD cases remain largely unknown.
- Novel research models are crucial for understanding CHD development and exploring new therapies.
Purpose of the Study:
- To review the utility of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes in CHD research.
- To highlight how hiPSC-derived cardiomyocytes can model CHD pathophysiology and identify therapeutic targets.
- To emphasize the potential of hiPSC-derived cardiomyocytes for personalized CHD research.
Main Methods:
- Utilizing hiPSC-derived cardiomyocytes to model gene regulatory networks in CHD.
- Investigating cell-cell and tissue interactions contributing to CHD using hiPSC models.
- Generating disease-specific cellular models from hiPSCs for mechanistic studies.
Main Results:
- hiPSC-derived cardiomyocytes provide a platform to study CHD development and pathophysiology.
- These models facilitate the exploration of gene regulatory and cellular interactions in CHD.
- Personalized hiPSC models enable disease-specific investigations.
Conclusions:
- hiPSC-derived cardiomyocytes are valuable tools for advancing CHD research.
- They offer unprecedented opportunities to understand molecular mechanisms and uncover therapeutic targets for CHD.
- Personalized hiPSC-based models hold significant promise for future CHD therapies.
Abstract:
Congenital heart disease (CHD) remains a significant health problem, with a growing population of survivors with chronic disease. Despite intense efforts to understand the genetic basis of CHD in humans, the etiology of most CHD is unknown. Furthermore, new models of CHD are required to better understand the development of CHD and to explore novel therapies for this patient population. In this review, we highlight the role that human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes can serve to enhance our understanding of the development, pathophysiology and potential therapeutic targets for CHD. We highlight the use of hiPSC-derived cardiomyocytes to model gene regulatory interactions, cell-cell interactions and tissue interactions contributing to CHD. We further emphasize the importance of using hiPSC-derived cardiomyocytes as personalized research models. The use of hiPSCs presents an unprecedented opportunity to generate disease-specific cellular models, investigate the underlying molecular mechanisms of disease and uncover new therapeutic targets for CHD.
